{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"486.53","value":"471.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"}],"units":"Participants"}],"title":"Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1050.76","value":"2187.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"}],"units":"Participants"}],"title":"Postdose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Idelalisib 150 mg tablet administered orally twice daily until tumor progression or development of unacceptable toxicity.","id":"OG000","title":"Idelalisib"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic (PK) Analysis Set included participants in the ITT Analysis Set who had the necessary baseline and on-study measurements.","reportingStatus":"POSTED","timeFrame":"Predose and at 1.5 hours (± 5 minutes) postdose on Day 29","title":"Idelalisib Plasma Concentration","type":"SECONDARY","unitOfMeasure":"ng/mL"}